Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) FCF Margin (2018 - 2025)

Historic FCF Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 15.48%.

  • Exagen's FCF Margin rose 340500.0% to 15.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.6%, marking a year-over-year decrease of 72500.0%. This contributed to the annual value of 25.15% for FY2024, which is 39400.0% up from last year.
  • Latest data reveals that Exagen reported FCF Margin of 15.48% as of Q3 2025, which was up 340500.0% from 17.62% recorded in Q2 2025.
  • In the past 5 years, Exagen's FCF Margin registered a high of 59.88% during Q4 2023, and its lowest value of 164.54% during Q2 2022.
  • Its 5-year average for FCF Margin is 44.54%, with a median of 47.83% in 2022.
  • As far as peak fluctuations go, Exagen's FCF Margin crashed by -1241100bps in 2022, and later skyrocketed by 1077100bps in 2023.
  • Exagen's FCF Margin (Quarter) stood at 56.04% in 2021, then increased by 15bps to 47.83% in 2022, then skyrocketed by 225bps to 59.88% in 2023, then plummeted by -100bps to 0.11% in 2024, then skyrocketed by 13990bps to 15.48% in 2025.
  • Its FCF Margin was 15.48% in Q3 2025, compared to 17.62% in Q2 2025 and 69.99% in Q1 2025.